Author

C. Ercan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genomics· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:DNA methylation· 1

Frequent Co-Authors

C. K. Ng· 2 shared L. M. Terracciano· 2 shared M. S. Matter· 2 shared S. Piscuoglio· 2 shared A. Dahmani· 1 shared A. Geng· 1 shared A. Schmidt· 1 shared A. Singanayagam· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

C. K. Ng

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting the expansion of myeloid-derived suppressor cells in liver cirrhosis

E. E. Flint, C. Ercan, E. Mitchell, O. T. Pop, A. Geng, P. Jorzik, L. A. Possamai, R. G. Brenig, S. Morel, P. Sieber, A. Singanayagam, M. S. Matter, D. Semela, M. H. E. Heim, P. Demougin, , C. Bernsmeier

This study investigates MDSC expansion in cirrhosis patients and murine models, showing poly(I:C) reduces MDSC and fibrosis in infected fibrotic mice.

bioRxiv · Mar 29, 2024 · PreprintImmunology

Proteogenomic characterization of hepatocellular carcinoma

C. K. Ng, E. Dazert, T. Boldanova, M. Coto-Llerena, S. Nuciforo, C. Ercan, A. Suslov, M.-A. Meier, T. Bock, A. Schmidt, S. Ketterer, X. Wang, S. Wieland, M. S. Matter, M. Colombi, , M. H. Heim

This study identifies differentially regulated pathways and candidate driver genes in hepatocellular carcinomas through proteogenomic analysis across clinical stages and etiologies.

bioRxiv · Mar 5, 2021 · PreprintGenomics

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

G. Bianco, M. Coto Llerena, J. Gallon, S. Taha-Mehlitz, V. Kancherla, M. Konantz, S. Srivatsa, H. Montazeri, F. Panebianco, M. De Menna, V. Paradiso, C. Ercan, A. Dahmani, E. Montaudon, N. Beerenwinkel, , S. Piscuoglio

This study identifies GATA3 and MDM2 as synthetic lethal in ER-positive breast cancers, showing MDM2 inhibition can target GATA3-deficient tumors via the PI3K/Akt/mTOR pathway.

bioRxiv · May 18, 2020Cancer Biology